Cargando…

Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes

This study aimed to examine whether the diagnostic accuracy of four noninvasive tests (NITs) for detecting advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is maintained or is inferior to with or without the presence of type 2 diabetes. Overall, 874 patients with biopsy‐proven NAFLD wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishiba, Hiroshi, Sumida, Yoshio, Seko, Yuya, Tanaka, Saiyu, Yoneda, Masato, Hyogo, Hideyuki, Ono, Masafumi, Fujii, Hideki, Eguchi, Yuichiro, Suzuki, Yasuaki, Yoneda, Masashi, Takahashi, Hirokazu, Nakahara, Takashi, Mori, Kojiro, Kanemasa, Kazuyuki, Shimada, Keiji, Imajo, Kento, Yamaguchi, Kanji, Kawaguchi, Takumi, Nakajima, Atsushi, Chayama, Kazuaki, Shima, Toshihide, Fujimoto, Kazuma, Okanoue, Takeshi, Itoh, Yoshito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034577/ https://www.ncbi.nlm.nih.gov/pubmed/33860115 http://dx.doi.org/10.1002/hep4.1637

Ejemplares similares

Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
por: Sumida, Yoshio, et al.
Publicado: (2012)

A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD
por: Kawaguchi, Takumi, et al.
Publicado: (2018)

Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
por: Sumida, Yoshio, et al.
Publicado: (2020)

Potential Therapeutic Targets and Promising Agents for Combating NAFLD
por: Umemura, Atsushi, et al.
Publicado: (2022)

Epidemiology, Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan
por: Sumida, Yoshio, et al.
Publicado: (2020)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic
por: Sumida, Yoshio, et al.
Publicado: (2021)

Discordant pathological diagnosis of non‐alcoholic fatty liver disease: A prospective multicenter study
por: Kuwashiro, Takuya, et al.
Publicado: (2019)

Decrease in fasting insulin secretory function correlates with significant liver fibrosis in Japanese non‐alcoholic fatty liver disease patients
por: Araki, Norimasa, et al.
Publicado: (2020)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Infection phase is a predictor of pruritus in patients with hepatitis B virus infection
por: Oeda, Satoshi, et al.
Publicado: (2019)

Modification of a simple clinical scoring system as a diagnostic screening tool for non‐alcoholic steatohepatitis in Japanese patients with non‐alcoholic fatty liver disease
por: Nakamura, Akinobu, et al.
Publicado: (2013)

Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods
por: Yoneda, Masato, et al.
Publicado: (2017)

Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin
por: Ogawa, Yuji, et al.
Publicado: (2018)

Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study
por: Honda, Yasushi, et al.
Publicado: (2017)

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
por: Yoneda, Masato, et al.
Publicado: (2022)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
por: Seko, Yuya, et al.
Publicado: (2018)

Are Platelets Count Useful for Detecting the Grade of Steatosis?
por: Imajo, Kento, et al.
Publicado: (2015)

Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
por: Kamada, Yoshihiro, et al.
Publicado: (2017)

Eradication of hepatitis C virus with direct‐acting antivirals improves glycemic control in diabetes: A multicenter study
por: Takahashi, Hirokazu, et al.
Publicado: (2020)

Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD
por: Nogami, Asako, et al.
Publicado: (2022)

Comparisons of dietary intake in Japanese with non-alcoholic fatty liver disease and type 2 diabetes mellitus
por: Kobayashi, Yukiko, et al.
Publicado: (2016)

Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring
por: Honda, Fumi, et al.
Publicado: (2018)

Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Honda, Yasushi, et al.
Publicado: (2020)

Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution
por: Nozaki, Yuichi, et al.
Publicado: (2015)

LDL-Migration Index (LDL-MI), an Indicator of Small Dense Low-Density Lipoprotein (sdLDL), Is Higher in Non-Alcoholic Steatohepatitis than in Non-Alcoholic Fatty Liver: A Multicenter Cross-Sectional Study
por: Imajo, Kento, et al.
Publicado: (2014)

Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease
por: Hotta, Kikuko, et al.
Publicado: (2010)

Glycogen Hepatopathy: An Under-recognized Hepatic Complication of Uncontrolled Type 1 Diabetes Mellitus
por: Sumida, Yoshio, et al.
Publicado: (2017)

Relationship between Streptococcus mutans expressing Cnm in the oral cavity and non-alcoholic steatohepatitis: a pilot study
por: Tonomura, Shuichi, et al.
Publicado: (2019)

Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease
por: Yoneda, Masato, et al.
Publicado: (2012)

The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD
por: Kamada, Yoshihiro, et al.
Publicado: (2022)

Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-β1/SMAD Signaling and Autophagy in Hepatic Stellate Cells
por: Kataoka, Seita, et al.
Publicado: (2021)

Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan
por: Yano, Kota, et al.
Publicado: (2020)

SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum
por: Kamada, Yoshihiro, et al.
Publicado: (2022)

Choline Deficiency Causes Colonic Type II Natural Killer T (NKT) Cell Loss and Alleviates Murine Colitis under Type I NKT Cell Deficiency
por: Sagami, Shintaro, et al.
Publicado: (2017)

PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat
por: Okishio, Shinya, et al.
Publicado: (2020)

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
por: Nakajima, Atsushi, et al.
Publicado: (2021)

The Appropriate Opportunity for Evaluating Liver Fibrosis by Using the FIB-4 Index in Patients with Nonalcoholic Fatty Liver Disease in Japan
por: Seko, Yuya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_la07au183uu9c7llar8addg6qd